Sotera Health swings to profit on 10% revenue growth; capex doubles as EO settlement paid

Filed May 5, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~1 min read

Key Changes

• high

  Net income turned positive at $26.6M vs. $13.3M loss a year ago, driven by 10% revenue growth to $280M, lower amortization (intangibles fully amortized May 2025), and 15% drop in interest expense from $75M debt paydown and 94-bp rate decline.

  MD&A: Results of Operations verify on EDGAR →
• high

  Adjusted EBITDA grew 10.5% to $134.7M, reflecting operational leverage from pricing gains and volume/mix improvements in Sterigenics and Nordion, partially offset by higher employee compensation.

  MD&A: Adjusted EBITDA verify on EDGAR →
• high

  Capital expenditures more than doubled to $46.2M from $19.9M, funding new facilities, business expansion, Co-60 inventory for gamma sites, and IT enhancements—signaling growth investment but higher near-term cash outflows.

  MD&A: Liquidity and Capital Resources verify on EDGAR →